Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Portfolio Pulse from
Arbutus' Imdusiran, in combination with interferon, has achieved a functional cure in 50% of chronic Hepatitis B patients with baseline HBsAg levels under 1000 IU/mL in a Phase 2a trial.
November 15, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arbutus' Imdusiran, combined with interferon, achieved a functional cure in 50% of chronic Hepatitis B patients with low baseline HBsAg levels in a Phase 2a trial.
The successful trial results for Imdusiran in achieving a functional cure for chronic Hepatitis B patients are likely to positively impact Arbutus' stock price. This development is significant for the company's product pipeline and future revenue potential.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90